ArkVax is a company headquartered in the United Kingdom.
ArkVax develops advanced glycan-based glycoconjugate vaccines for animals using bacterial glycoengineering to improve vaccine potency and breadth while addressing antimicrobial resistance and zoonotic disease protection.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.